Fructose Turns the Famine Signal On | The Starved Brain, Chapter 7

Metaflammation screening

Metaflammation Screening: What the Standard Panel Misses

Metaflammation screening in primary care measures what the standard panel misses: fasting glucose and HbA1c flag only the patient whose compensation has already failed. Waist circumference, body composition, measured resting energy expenditure, fasting insulin, uric acid, hs-CRP and oxidized LDL fill the gap, starting with patients who carry central adiposity at any BMI.

Chronic metabolic inflammation is clinically silent, and the panel most practices order was never designed to find it. The practical questions are who to measure, with what, and what a result changes.

Metaflammation, Hotamisligil’s term for chronic inflammation driven by metabolic excess, has a screening problem built into its definition: it produces no findings on examination and no complaint at the front desk. The chapter video, Fructose Turns the Famine Signal On, lays out the case from The Starved Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP that fructose load, visceral fat and diet-related endotoxin keep that inflammation running, with consequences reaching the brain. Measura [Cardiometabolic and Autonomic Health Analysis] is a testing protocol, not a treatment service, so the relevant question for a practice is operational. Which patients should be measured, which measurements add information the routine panel does not, and what does a result change?

The evidence tier, stated once

The fructose argument is a hypothesis. Johnson’s 2020 paper reports no trial and no new cohort, and four of its eight authors declared equity in a company developing inhibitors of fructose metabolism. The human data underneath it come from liver, not brain: in 25 obese adults with type 2 diabetes studied by phosphorus spectroscopy, those eating 15 g of fructose a day or more showed a greater fall in hepatic ATP, and those with uric acid at or above 5.5 mg/dL reached a lower nadir. The brain chain is thinner still. Two links are human: systemic inflammatory events in 222 community patients with Alzheimer’s disease meant 3.5 ADAS-Cog points lost over six months against 1.6, and synapse loss tracks cognition in small autopsy series. The middle, metabolic excess priming microglia that then strip synapses, is mouse work, and the human imaging is split: HOMA-IR tracked cortical TSPO binding in 57 unimpaired elders, while 12 BMI-discordant identical twin pairs showed no excess in the heavier twin. That tier does not argue against measuring. It argues against promising what a measurement predicts.

What does a standard metabolic panel miss?

Fasting glucose and HbA1c identify the patient whose compensation has already failed. They say nothing about fat distribution, lean mass, resting energy expenditure or inflammatory tone. The more interesting gap is in data already on the chart. Across 23 cohorts and 947,020 participants, a higher neutrophil-to-lymphocyte ratio predicted incident dementia, HR 1.24 (1.15–1.34), with heterogeneity high at I² of 95%. In 161,968 UK Biobank adults, the neutrophil count carried HR 1.08 while the linear CRP hazard sat at 0.95. Cell counts associate with dementia more consistently than CRP does, and a CBC is drawn at nearly every visit for some other reason. Reverse causation is excluded by none of these cohorts, so the ratio is a flag for a closer look, not a result to act on alone.

High-sensitivity CRP still has a place, read on the scale it was built for: the AHA/CDC bands of under 1 mg/L, 1 to 3 and above 3 are cardiovascular risk tertiles, and a value above 10 calls for a repeat and a search for infection. Pooled data put high CRP ahead of conversion to dementia, HR 1.473, without predicting decline on cognitive tests.

Who should be screened for metaflammation?

The selection logic follows the mechanism rather than the diagnosis list. Central adiposity at any BMI qualifies, because waist circumference was associated with mortality within every BMI band from 20 to 50 kg/m², rising 17% in men and 13% in women per 5 cm at a given BMI. So does the patient with normal glucose but a family history, a rising waist or an elevated uric acid, which reads fructose load and is not a validated dementia marker in either direction. Cognitive complaints in a patient carrying that metabolic picture belong on the list too. There is a structural driver worth naming: added sugars supply roughly 15% of energy in the U.S. food supply, and up to 20% or more in some groups, so exposure is set by what is on the shelf, not by a patient’s individual choices. And one non-obvious point on evidence: the fifteen randomized trials that cleared linoleic acid of raising inflammatory markers enrolled healthy people. None enrolled the insulin-resistant patient most practices are trying to screen. The criteria page sets this out in operational form (selection criteria).

Which tests measure metaflammation?

Bioimpedance body composition separates fat from lean mass, the distinction BMI erases and the one that matters when visceral fat is the IL-6 source: in 25 extremely obese adults sampled during bypass surgery, portal IL-6 ran about 50% above arterial levels and correlated with CRP. Indirect calorimetry replaces a predicted resting energy expenditure with a measured one. Laboratory panels carry the chemistry: fasting insulin reported on its own, uric acid, hs-CRP, and oxidized LDL with the omega-6 to omega-3 ratio. In CARDIA, among 1,889 adults without metabolic syndrome at baseline, the top quintile of oxidized LDL carried OR 3.5 (1.9–6.6) for developing it within five years, and LDL cholesterol predicted nothing once oxidized LDL entered the model. Assays differ in antibodies and units, so values from different methods cannot be compared directly; pick one method and trend it.

Where the metabolic picture is abnormal and cognition is part of the concern, a cognitive assessment gives a documented baseline. That pairing also feeds fall prevention, since cognitive and balance workups share a patient population and a visit structure (cognitive assessment and fall prevention).

What a finding changes

Measura does not diagnose on its own, and results return to the ordering physician. What a finding changes is the specificity of the conversation. A patient told the A1C is fine hears permission; a patient shown visceral fat, a measured resting energy expenditure and an oxidized LDL in the top of its assay’s range hears a problem with coordinates. It changes follow-up: a defined interval to repeat the same measurements on the same method, so dietary change aimed at added sugar and processed food can be checked against numbers rather than weight alone. It also changes how a CRP above 10 is handled, as a repeat and an infection search, not as metabolic inflammation. None of it requires a medication decision to be useful.

Documentation and workflow

Record waist circumference as a vital sign next to BMI. Place the cognitive baseline in the annual wellness visit note where it can be compared year over year, and let standing orders define eligibility so screening does not depend on who had time that afternoon (standing orders for screening). Structured results that land in discrete fields support MIPS and HEDIS documentation far better than scanned reports (MIPS and quality reporting). The patient-facing version of this material is written separately (the patient article on sugar and inflammation), the full referenced evidence sits in the book companion (Chapter 7 companion), and the next physician article takes the same inflammatory argument into periodontal disease (periodontal disease and dementia).

Frequently asked questions

Is hs-CRP a reasonable proxy for metaflammation?

Partly. CRP is the hepatic footprint of IL-6, including IL-6 from the visceral depot, so it reflects some of the load. Its validated bands are cardiovascular. For brain outcomes it is inconsistent: pooled data tie high CRP to dementia conversion, while midlife CRP in 12,336 ARIC participants predicted only a small decline over 20 years. Read it with body composition and cell counts, not alone. Guidance on reading the combined report is in interpreting the report.

Should oxidized LDL replace LDL cholesterol in screening?

It adds rather than replaces. In CARDIA it predicted incident metabolic syndrome independent of LDL cholesterol, and in 3,987 non-diabetic PESA adults the top quartile carried OR 2.57 after adjustment for waist and HOMA-IR, though that analysis was cross-sectional. The limitation is analytic: no shared reference range exists across assays. Use one laboratory method consistently and interpret trend. The broader case is in clinical rationale.

Is uric acid worth ordering if it is not a dementia marker?

Yes, for what it does measure. Serum urate climbs by 0.3 to 2.0 mg/dL in the first hour after a fructose dose, and in the liver spectroscopy study patients at or above 5.5 mg/dL had the deeper energy fall. For dementia the cohorts point both ways and Mendelian randomization was null. Treat it as a fructose-load signal in the metabolic workup. Examples of where it sits in different practices are in specialty applications.

How often should these measurements be repeated?

Often enough to see whether management moved them, and always on the same method, since assay changes can masquerade as clinical change. Body composition and resting energy expenditure respond on a slower timescale than a single inflammatory marker, which can swing with an intercurrent infection. Build the interval into the order set rather than leaving it to recall. A general framework is in how often to repeat cardiometabolic testing.

How do results reach the chart in usable form?

The value of a baseline depends on retrieving it a year later, which scanned PDFs make difficult. Discrete results mapped to the record let waist, body composition, laboratory values and cognitive scores be trended alongside the problem list and pulled into quality documentation. Options for integration are described in getting results into the record.

What is metaflammation?

Metaflammation is Hotamisligil’s term for chronic inflammation driven by metabolic excess. It is low-grade, runs through the whole body and produces no findings on examination and no complaint at the front desk. The case laid out in The Starved Brain is that fructose load, visceral fat and diet-related endotoxin keep it running, with consequences reaching the brain. That silence is why it has to be measured.

What are the symptoms of metabolic inflammation?

Usually none a patient reports. Metaflammation is clinically silent, and fasting glucose and HbA1c stay normal until compensation has already failed. What shows it is measurement: a waist circumference out of proportion to BMI, the fat and lean split on body composition, a measured resting energy expenditure, fasting insulin, uric acid, hs-CRP and oxidized LDL, read together and trended on the same method.

Does a normal A1C rule out metaflammation?

No. Fasting glucose and HbA1c identify the patient whose compensation has already failed. They say nothing about fat distribution, lean mass, resting energy expenditure or inflammatory tone. A patient told the A1C is fine hears permission; a patient shown visceral fat, a measured resting energy expenditure and an oxidized LDL near the top of its range hears a problem with coordinates.

See how the Measura protocol fits your practice

Learn how metabolic, body composition and cognitive measurements are ordered, reported and documented within an existing primary care or specialty workflow.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Johnson, R. J., Gomez-Pinilla, F., Nagel, M., Nakagawa, T., Rodriguez-Iturbe, B., Sanchez-Lozada, L. G., Tolan, D. R., & Lanaspa, M. A. (2020). Cerebral fructose metabolism as a potential mechanism driving Alzheimer’s disease. Frontiers in Aging Neuroscience, 12, Article 560865. https://doi.org/10.3389/fnagi.2020.560865
Abdelmalek, M. F., Lazo, M., Horska, A., Bonekamp, S., Lipkin, E. W., Balasubramanyam, A., Bantle, J. P., Johnson, R. J., Diehl, A. M., Clark, J. M., & the Fatty Liver Subgroup of the Look AHEAD Research Group (2012). Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology, 56(3), 952–960. https://doi.org/10.1002/hep.25741
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009). Systemic inflammation and disease progression in Alzheimer disease. Neurology, 73(10), 768–774. https://doi.org/10.1212/WNL.0b013e3181b6bb95
Toubasi, A. A., & Al-Sayegh, T. N. (2026). Peripheral immune markers in dementia: A systematic review and meta-analysis of risk, severity, and pathological correlates. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 12(2), e70270. https://doi.org/10.1002/trc2.70270
Zhong, X., Qiang, Y., Wang, L., Zhang, Y., Li, J., Feng, J., Cheng, W., Tan, L., & Yu, J. (2023). Peripheral immunity and risk of incident brain disorders: a prospective cohort study of 161,968 participants. Translational Psychiatry, 13(1), 382. https://doi.org/10.1038/s41398-023-02683-0
Ross, R., Neeland, I. J., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., Cuevas, A., Hu, F. B., Griffin, B. A., Zambon, A., Barter, P., Fruchart, J.-C., Eckel, R. H., Matsuzawa, Y., & Després, J.-P. (2020). Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nature Reviews Endocrinology, 16(3), 177–189. https://doi.org/10.1038/s41574-019-0310-7
Holvoet, P., Lee, D.-H., Steffes, M., Gross, M., & Jacobs, D. R. (2008). Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA, 299(19), 2287–2293. https://doi.org/10.1001/jama.299.19.2287
Ekblad, L. L., Tuisku, J., Koivumäki, M., Helin, S., Rinne, J. O., & Snellman, A. (2023). Insulin resistance and body mass index are associated with TSPO PET in cognitively unimpaired elderly. Journal of Cerebral Blood Flow and Metabolism, 43(9), 1588–1600. https://doi.org/10.1177/0271678X231172519
Fontana, L., Eagon, J. C., Trujillo, M. E., Scherer, P. E., & Klein, S. (2007). Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 56(4), 1010–1013. https://doi.org/10.2337/db06-1656
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., Rifai, N., Smith, S. C., Taubert, K., Tracy, R. P., & Vinicor, F. (2003). Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107(3), 499–511. https://doi.org/10.1161/01.CIR.0000052939.59093.45